GSK716155 (formerly Albugon), a novel long-acting form of glucagon-like peptide-1 (GLP-1), is in clinical trials for the treatment of Type 2 diabetes. It was created using Human Genome Sciences' proprietary albuminfusion technology, which involves fusing the gene that expresses human albumin to the gene that expresses a therapeutically active protein.
Investigated for use/treatment in diabetes mellitus type 2.
Mechanism of action
GSK716155, a GLP-1 receptor agonist, has been shown to have multiple physiologic activities in the central nervous system and gastrointestinal system that could lower A1C. It increases peripheral glucose uptake, enhances insulin secretion, decreases glucagon secretion, delays gastric emptying, reduces food intake and induces satiety at CNS.